Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05798663
Title Atezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unresectable Stage III NSCLC
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Alliance Foundation Trials, LLC.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST